Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine ( AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

被引：50
|
作者：
Gojo, Ivana [1 ]
Stuart, Robert K. [2 ]
Webster, Jonathan [1 ]
Blackford, Amanda [3 ]
Varela, Juan Carlos [4 ]
Morrow, Jillian [1 ]
DeZern, Amy E. [1 ]
Foster, Matthew C. [5 ]
Levis, Mark J. [1 ]
Coombs, Catherine C. [5 ]
Prince, Gabrielle T. [6 ]
Smith, B. Douglas [7 ]
Van Deventer, Hendrik W. [5 ]
Jamieson, Katarzyna [5 ]
Varadhan, Ravi [1 ]
Vincent, Benjamin G. [5 ]
Serody, Jonathan S. [5 ]
Luznik, Leo [1 ]
Zeidner, Joshua F. [5 ]
机构：
[1] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[2] Med Univ South Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA
[3] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[4] Florida Hosp, Blood & Marrow Transplant Ctr, Orlando, FL USA
[5] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA
[6] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA
[7] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Johns Hopkins Med Inst, Baltimore, MD USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-127345
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
832
引用
收藏
页数：5
相关论文
共 50 条
  • [21] A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML)
    Pollyea, Daniel A.
    Kohrt, Holbrook E.
    Gallegos, Leonel
    Berube, Caroline
    Coutre, Steven
    Gotlib, Jason
    Liedtke, Michaela
    Mitchell, Beverly S.
    Medeiros, Bruno C.
    BLOOD, 2010, 116 (21) : 1347 - 1347
  • [22] THE EFFECT OF AZACITIDINE ON HEALTH-RELATED QUALITY OF LIFE (HRQL) IN OLDER PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM THE AZA-AML-001 TRIAL
    Minden, M. D.
    Dombret, H.
    Seymour, J. F.
    Stone, R. M.
    Alibhai, S.
    Nixon, A.
    Kudlac, A.
    Songer, S.
    Beach, C.
    Bartiromo, C.
    Doehner, H.
    HAEMATOLOGICA, 2015, 100 : 40 - 41
  • [23] Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III study
    Garcia-Manero, Guillermo
    Kazmierczak, Maciej
    Wierzbowska, Agnieszka
    Fong, Chun Yew
    Keng, Michael K.
    Ballinari, Gianluca
    Scarci, Francesco
    Ades, Lionel
    LEUKEMIA RESEARCH, 2024, 140
  • [24] First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab plus Azacitidine plus Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML)
    Jaddaoui, Samiha
    Bencharef, Hanaa
    Addakiri, Sara
    Dehbi, Hind
    Lamchahab, Mouna
    Quessar, Asmaa
    Madani, Abdellah
    Oukkache, Bouchra
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S255 - S256
  • [25] First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab plus Azacitidine plus Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML)
    Zeidan, Amer M.
    Westermann, Joerg
    Kovacsovics, Tibor
    Assouline, Sarit
    Schuh, Andre C.
    Kim, Hee-Je
    Macias, Gabriela Rodriguez
    Sanford, David
    Luskin, Marlise R.
    Stein, Eytan M.
    Malek, Kamel
    Lyu, Jiaying
    Stegert, Mario
    Esteve, Jordi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S255 - S255
  • [26] Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML)
    Ball, Brian J.
    Arslan, Shukaib
    Koller, Paul
    Ngo, Dat
    Afkhami, Michelle
    Salhotra, Amandeep
    Al-Malki, Monzr
    Aribi, Ahmed
    Ali, Haris
    Sandhu, Karamjeet
    Otoukesh, Salman
    Amanam, Idoroenyi
    Pourhassan, Hoda
    Artz, Andrew
    Curtin, Peter
    Stein, Anthony
    Nakamura, Ryotaro
    Marcucci, Guido
    Smith, Eileen
    Pullarkat, Vinod
    Aldoss, Ibrahim
    LEUKEMIA & LYMPHOMA, 2022, 63 (13) : 3232 - 3236
  • [27] Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and Cytarabine) Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML): Early Results
    Klisovic, Rebecca B.
    Wang, Hongyan
    Walker, Alison
    Walsh, Katherine
    Vasu, Sumithira
    Garzon, Ramiro
    Devine, Steven M.
    Wang, Jiang
    Garr, Celia
    Norris, Adam
    Byrd, John C.
    Grever, Michael R.
    Blum, William
    Chan, Kenneth K.
    Marcucci, Guido
    BLOOD, 2012, 120 (21)
  • [28] EFFICACY AND SAFETY OF AZACITIDINE (AZA) VERSUS CONVENTIONAL TREATMENT (TC) IN PATIENTS=75 YEARS WITH ACUTE MYELOBLASTIC LEUKEMIA (AML) IN THE PHASE III STUDY AZA AML001
    Bargay Lleonart, J.
    Seymour, J. F.
    Buckstein, R.
    Santini, V
    Doehner, H.
    Stone, R. M.
    Minden, M. D.
    Ching, Kuo Y.
    Ben Yehuda, D.
    Songer, S.
    Weaver, J.
    Beach, C. L.
    Dombret, H.
    HAEMATOLOGICA, 2017, 102 : 176 - 177
  • [29] THE SAFETY AND EFFICACY OF AZACITIDINE IN PATIENTS WITH NEWLY-DIAGNOSED AND REFRACTORY/RELAPSED AML NOT ELIGIBLE FOR OR RESISTANT TO CHEMOTHERAPY: A MULTI-CENTER PHASE I/II-STUDY OF THE EAST GERMAN HAEMATOLOGY AND ONCOLOGY STUDY GROUP (OSHO)
    Al-Ali, H. K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 343 - 343
  • [30] Mutant Isocitrate Dehydrogenase (mIDH) Inhibitors, Enasidenib or Ivosidenib, in Combination with Azacitidine (AZA): Preliminary Results of a Phase 1b/2 Study in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
    DiNardo, Courtney D.
    Stein, Anthony S.
    Fathi, Amir T.
    Montesinos, Pau
    Odenike, Olatoyosi
    Kantarjian, Hagop M.
    Stone, Richard M.
    Koralek, Daniel O.
    Van Oostendorp, Jason
    Gong, Jing
    Gupta, Ira
    Vyas, Paresh
    BLOOD, 2017, 130
12345